Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective for advanced Hodgkin's disease. PURPOSE: Randomized phase III trial to compare different combination chemotherapy regimens in treating patients with advanced Hodgkin's disease.

Timeline

Start

1998-06

Primary completion

—

Completion

2005-11

Outcome

Missed primary endpoint

paper at 3 years EFS was 75% (95% CI, 71% to 79%) for ABVD and 75% (95% CI, 70% to 79%) for MDRs PMID 16314615 ↗

paper There was no evidence of significant difference in EFS or OS between ABVD and MDRs in the trial overall PMID 16314615 ↗

Publications

• Results Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, MacLennan KA, Stenning SP, Clawson S, Smith P, Ryder D, Hancock BW; United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol. 2005 Dec 20;23(36):9208-18. doi: 10.1200/JCO.2005.03.2151. Epub 2005 Nov 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bleomycin	Unknown	—	Intravenous
Subject	Chlorambucil	Other / unclassified	—	Oral
Subject	Dacarbazine	Small molecule	—	Intravenous
Subject	Doxorubicin	Other / unclassified	—	Intravenous
Subject	Etoposide	Small molecule	—	Oral
Subject	Prednisolone	Other / unclassified	—	Oral
Subject	Vinblastine	Small molecule	—	Intravenous
Subject	Vincristine	Small molecule	—	Intravenous
Subject	procarbazine	Small molecule	—	Oral

Indications